Neuron23(TM) Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group

Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Neuron23™ Inc., an e... Biopharmaceuticals, Neurology, Venture Capital Neuron23, precision medicine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news